drugset / Trial / NCT05276232
Detection of Cannabis Impairment With ISBRG's SpotLight-THC
Non-randomizedParallel-groupOpen-labelBasic science
Summary
Subjects will participate in a 2-visit study protocol in which they will be administered cannabis of pre-determined concentrations and asked to complete a simulated drive in a driving simulator. Subjects will be scanned on two SpotLight-THC (Alpha and Beta iterations) devices and peripheral venous whole blood will be collected from subjects for analysis on up to four occasions on each visit. The purpose of the investigation will be to determine whether the SpotLight-THC device is a reliable measure of THC impairment at the roadside, with an objective to identify a unique blood analyte architecture for THC impairment using near infrared light and machine learning.
Timeline
- Start
- 2022-03
- Primary completion
- 2022-08
- Completion
- 2022-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | THC | Unknown | 30 mg | Inhaled |
| Subject | THC | Unknown | 37.5 mg | Inhaled |
Indications
No indication recorded.